VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Age ≥ 18 years                                     │ Age ≥ 18 years                                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient with breast cancer, histologically proven, │ Patient with breast cancer, histologically proven, │     100 │
│ metastatic or locally advanced                     │ metastatic or locally advanced                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient treated by Eribulin between January and    │ Patient treated by Eribulin between January and    │     100 │
│ October 2014 (for the retrospective part) or       │ October 2014 (for the retrospective part) or       │         │
│ between November 2014 and September 2015 (for the  │ between November 2014 and September 2015 (for the  │         │
│ prospective part)                                  │ prospective part)                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient with at least an assessment of the         │ Patient with at least an assessment of the         │     100 │
│ response to Eribulin                               │ response to Eribulin                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of other neoplasia                        │ Presence of other neoplasia                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Man                                                │ Man                                                │     100 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria               │   Score │
╞═══════════════════════════════════╪═════════════════════════════╪═════════╡
│ Must be FEMALE                    │ Presence of other neoplasia │      20 │
├───────────────────────────────────┼─────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Age ≥ 18 years              │      47 │
╘═══════════════════════════════════╧═════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 94
Average Levenshtein Ratio of individual lines: 83.375
OverAll Ratio: 88.6875
